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Abstract
Induction of general anesthesia frequently induces arterial hypotension, which is often treated with a vasopressor, such as 
phenylephrine. As a pure α-agonist, phenylephrine is conventionally considered to solely induce arterial vasoconstriction and 
thus increase cardiac afterload but not cardiac preload. In specific circumstances, however, phenylephrine may also contrib-
ute to an increase in venous return and thus cardiac output (CO). The aim of this study is to describe the initial time course 
of the effects of phenylephrine on various hemodynamic variables and to evaluate the ability of advanced hemodynamic 
monitoring to quantify these changes through different hemodynamic variables. In 24 patients, after induction of anesthe-
sia, during the period before surgical stimulus, phenylephrine 2 µg kg−1 was administered when the MAP dropped below 
80% of the awake state baseline value for > 3 min. The mean arterial blood pressure (MAP), heart rate (HR), end-tidal  CO2 
 (EtCO2), central venous pressure (CVP), stroke volume (SV), CO, pulse pressure variation (PPV), stroke volume variation 
(SVV) and systemic vascular resistance (SVR) were recorded continuously. The values at the moment before administra-
tion of phenylephrine and 5(T5) and 10(T10) min thereafter were compared. After phenylephrine, the mean(SD) MAP, SV, 
CO, CVP and  EtCO2 increased by 34(13) mmHg, 11(9) mL, 1.02(0.74) L min−1, 3(2.6) mmHg and 4.0(1.6) mmHg at  T5 
respectively, while both dynamic preload variables decreased: PPV dropped from 20% at baseline to 9% at  T5 and to 13% at 
 T10 and SVV from 19 to 11 and 14%, respectively. Initially, the increase in MAP was perfectly aligned with the increase in 
SVR, until 150 s after the initial increase in MAP, when both curves started to dissociate. The dissociation of the evolution 
of MAP and SVR, together with the changes in PPV, CVP,  EtCO2 and CO indicate that in patients with anesthesia-induced 
hypotension, phenylephrine increases the CO by virtue of an increase in cardiac preload.
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1 Introduction
The ultimate goal of hemodynamic management is to 
maintain adequate tissue oxygen delivery to the different 
end-organs [1]. Surgical patients often suffer relative hypo-
volemia owing to a combination of epidural analgesia, gen-
eral anesthesia and patient positioning. The principal aim 
of goal-directed fluid therapy is to optimize the position of 
the heart on the Frank–Starling curve by increasing cardiac 
preload. This is conventionally pursued by administration of 
fluids to increase total blood volume and can improve patient 
outcome by reducing postoperative complications and length 
of hospital stay [2].
Phenylephrine is a direct α-adrenergic receptor ago-
nist, predominantly α1, increasing the systemic vascular 
resistance (SVR) and arterial pressure [3]. While venous 
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α1 receptor activity is acknowledged scientifically, in most 
clinical conditions, phenylephrine is considered to increase 
cardiac afterload but not cardiac preload. In patients with life 
threatening septic shock, norepinephrine has been shown to 
increase venous return in case of preload dependence [4, 5]. 
Nevertheless, while a beneficial effect of phenylephrine on 
the blood pressure is obviously well known, phenylephrine 
is conventionally postulated to have no effects on CO, but 
owing to an increase in afterload, would in most cases even 
decrease CO. In contrast, however, while an increase in left 
ventricular afterload may decrease stroke volume (SV) and 
thus cardiac output (CO) [6], the α1-adrenergic receptor 
stimulation—either by phenylephrine or norepinephrine—
also decreases venous capacitance, which could in turn 
increase cardiac preload and SV [3]. It has been shown in 
pigs that the impact of phenylephrine on the CO is related 
to preload dependency [7]. When the heart is preload inde-
pendent, phenylephrine induces on average a decrease in 
CO, whereas when the heart is preload dependent, it induces 
on average an increase in CO [6]. We hypothesize that in 
preload-dependent patients due to pronounced relative hypo-
volemia induced by combined epidural and general anes-
thesia, in leg-down position, phenylephrine may increase 
cardiac preload by virtue of centralisation of blood volume.
The aim of this study was to differentiate the chronic-
ity of the changes in cardiac preload and CO after a single 
administration of phenylephrine and to assess the ability 
of advanced hemodynamic monitoring to quantify these 
changes through different hemodynamic variables.
2  Methods
This prospective interventional study was approved by the 
institutional review board and was registered at clinicaltri-
als.gov (NCT:02739399; PI Dr. A Kalmar; April 15, 2016). 
The manuscript adheres to the applicable STROBE guide-
lines. After written informed consent was obtained, a total 
of 24 adult patients, scheduled for elective laparoscopic sig-
moidectomy were included (Fig. 1). Patients with cardiac 
arrhythmia or a contraindication for atropine or phenyle-
phrine administration were excluded.
2.1  Study protocol
No premedication was administered. Upon arrival in the 
operating theatre, a peripheral intravenous line was inserted 
and an epidural catheter was placed. After adequate pre-
oxygenation, induction and maintenance of anesthesia 
was pursued by target-controlled total i.v. anesthesia with 
propofol and remifentanil. At the start of induction of anes-
thesia, intravenous methylatropine 0.5 mg and epidural lev-
obupivacaine 50 mg were given. After the administration 
of cis-atracurium and endotracheal intubation, the patients’ 
lungs were mechanically ventilated in the volume con-
trol mode (tidal volume: 8 mL kg−1) with an  O2/air mix-
ture  (FiO2 0.6) and a PEEP of 4 cm  H2O. During the study 
period, the ventilatory settings were unchanged. A radial 
artery was cannulated using a 20 G catheter and connected 
with a disposable ProAQT transducer from the Pulsioflex 
monitor (Maquet, Rastatt, Germany)—all measurements 
were conducted with the same Pulsioflex monitor and auto-
matically calibrated. This minimal invasive device enables 
calculation of the mean arterial blood pressure (MAP), heart 
rate (HR), SV and CO using pulse contour analysis of the 
arterial pressure curve. In addition, it calculates pulse pres-
sure variation (PPV) and stroke volume variation (SVV) as 
measures of cardiac preload dependency as well as SVR as 
one of the determinants of left ventricular afterload. Next, a 
central venous catheter was placed for continuous recording 
of the central venous pressure (CVP) and the patient was 
positioned in preparation for surgery. All pressure transduc-
ers were located at the level of the right atrium before initia-
tion of the study period. During the subsequent period prior 
to surgical stimulus, when MAP dropped below 80% of the 
awake state baseline value for > 3 min, a bolus of phenyle-
phrine 2 µg kg−1 was administered. From 3 min before until 
13 min after phenylephrine administration, patient position-
ing was left unaltered, and no other medication or fluid was 
administered.
2.2  Data registration and analysis
All anesthetic data were collected on the anesthesia moni-
tor (Philips MP70; Philips, Eindhoven, The Netherlands) 
Fig. 1  Flow chart of the patients’ inclusion and analysis
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and recorded at 0.2 Hz for subsequent offline analysis. The 
electronic data were imported into Microsoft Excel 2010® 
(Microsoft, Redmond, USA) for analysis. In addition to the 
recorded variables, an analogue of the mean systemic fill-
ing pressure (Pmsa) was calculated using the formula Pms
a = a × CVP + b × MAP + c × CO, in which a = 0.96, b = 0.04 
and c is calculated according to anthropometric data [8]. 
Subsequently, resistance to venous return (RVR) was calcu-
lated as RVR = (Pmsa − CVP).  CO−1 and pressure for venous 
return (Pvr; as a measure of venous return) was calculated as 
Pvr = Pmsa − CVP.
The evolution of the absolute values and of the changes 
relative to baseline  (T−1) was analyzed from 1 min before 
induction  (T−1) of anesthesia until the relative steady state 
was achieved for all study variables after 10 min  (T10). All 
measurements for the study were performed before surgery 
commenced.
2.3  Statistical analysis
Assuming a normal distribution of the CO data, we considered 
a mean increase in CO of 15% to be clinically relevant (esti-
mated SD of 0.7 L min−1, based on pilot data). To detect this 
difference with an α-error of 0.05 and a power of 0.95, a total 
of 17 patients is needed [9]. A supplemental 40% of patients 
were included to anticipate exclusions, making a total of 24 
patients.
Normality and homoscedasticity were tested with the Kol-
mogorov–Smirnov test and modified Levine test, respectively. 
Continuous data are expressed as mean(SD). For statistical 
analysis and visualization, the individual patient measurements 
were synchronized at the moment  (T0) of 10 mmHg increase 
in MAP after phenylephrine administration.
For visual assessment of systematic changes of the main 
variables, the evolution of the individual patient values, as well 
as the evolution of the mean value were depicted in Fig. 2. For 
comprehensive visualization of the chronicity and interaction 
of the different variables, the average values of all the studied 
variables were shown in Fig. 3.
The absolute values of the analysed variables were deter-
mined at 1 min before the increase in MAP  (T−1), and 5(T5) 
and 10(T10) min afterwards. Results were subject to the gen-
eral linear model repeated measures ANOVA with Bonfer-
roni adjustment. All statistics were performed using S-PLUS 
8.0 (TIBCO Software Inc., Palo Alto, CA, USA) and SPSS 
23.0 (SPSS Inc., Chicago, IL, USA). Significance was set at 
P < 0.05.
3  Results
Six patients were excluded from analysis because of prede-
termined exclusion criteria: arrhythmia (n = 2), technical 
error, or absence of epidural analgesia, atropine, phenyle-
phrine need (Fig. 1). A total of 18 ASA 2–3 patients were 
included in the analysis (Fig. 1). The mean(SD) age was 
62(13) years, the weight was 74(12) kg, and the length 
was 165(7) cm.
The average(SD) CO increased from 3.92(0.87) L min−1 
at  T−1 to 4.94(1.2) L min−1 at  T5. Figure 2a–k shows the 
evolution in individual patients (thin lines) and average 
(thick line) values of the main hemodynamic variables 
during the period from 1 min before till 12 min after the 
increase in initial blood pressure. An overview of the chro-
nicity and interactions of the mean values of all the inves-
tigated variables is comprehensively depicted in Fig. 3.
Changes in hemodynamics are summarized in Table 1. 
Between  T−1 and  T5, MAP, SV, CO, CVP and  EtCO2 
increased by 62, 28, 26, 33 and 11%, respectively, while both 
dynamic preload variables decreased: PPV dropped from 
20% at  T−1 to 9% at  T5 and to 13% at  T10 and SVV from 19 
to 11 and 14%, respectively. Between  T−1 and  T5, the Pmsa 
increased by 37% and the Pvr by 41%. In addition, while 
the SVR increased by 37%, the RVR increased by 6% only.
4  Discussion
Phenylephrine is conventionally thought to negatively 
affect CO, or at best to have no influence if the cardiac 
contractility is able to overcome the increased afterload 
without loss of SV [10]. Our hypothesis, however, was on 
the contrary, that if a relative hypovolemia is present due 
to anesthesia-induced excessive vasodilation of the capaci-
tance vessels, this could be corrected by phenylephrine, 
inducing an improved centralization of the available blood, 
eventually resulting in an increase in CO.
The main finding of this prospective study was that in 
patients with anesthesia-induced hypotension and preload 
dependency—defined as PPV > 12%, phenylephrine 
increases CO by virtue of an increase in return function. 
This is reflected in multiple distinct indices, all indicating an 
increase in CO, owing to a rightward shift in the position of 
the heart on the Frank–Starling relationship: the dissociation 
of MAP and SVR at  T1, CVP, PPV, CO, and  EtCO2.
In patients undergoing sigmoidectomy, a relative hypov-
olemia is common owing to the combination of several fac-
tors: the patients have been fasting from the night before, had 
bowel preparation, and received an epidural loading dose, 
combined with general anesthesia, all causing vasodilation.
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This pharmacologically induced vasoplegia, together 
with gravitational venous pooling in the lower limbs due to 
the leg-down patient positioning—to prevent conflict with 
the surgeon’s arms—and an increase in abdominal pres-
sure often results in a markedly decreased venous return 
[11]. While an increase in cardiac preload enhances the CO, 
recent evidence revealed that a zero-balance fluid approach 
is recommended in the elective perioperative setting to avoid 
adverse effects of unnecessary, excessive fluid administra-
tion [12, 13]. In bowel surgery, the additional concern for 
return of peristalsis, and oedema of the gut tissue empha-
sizes the importance of moderating fluid administration. 
Fluid restriction is therefore considered a part of the care 
package for enhanced recovery after colorectal surgery [14].
Importantly, this relative hypovolemic state is just of 
temporary occurrence. When surgery ends, and the patient 
awakens, the venous tonus and consequently CO will 
increase again spontaneously. As such, an alternative to 
enhance venous return, other than the irrevocable admin-
istration of fluids would be desirable. In those cases, the 
option of recruiting internal blood volume by increasing 
venous return through reversible pharmacological means 
such as vasopressors acting predominantly on capacitance 
vessels might be a potential alternative.
In an animal study, the average effect of phenylephrine 
on CO was related to the preload dependency of the heart: 
when the heart was preload dependent, phenylephrine 
induced an increase in CO [7]. Similarly, in a study with 
human patients, CO and SV decreased in preload-independ-
ent patients through an increase in cardiac afterload, but by 
virtue of increased venous return were unchanged in those 
that were preload-dependent [6].
In contrast to most studies analysing the combined effects 
of phenylephrine [3], its beneficial effect on the return func-
tion is much more pronounced in our patients where the 
combination of general anesthesia, leg-down position and 
epidural analgesia—which reduces alpha tone—induced dis-
tinctly different physiological conditions [15]. The actual 
blood flow in the body is determined by the intersection 
of the cardiac function and the return function, the latter 
defined by the stressed blood volume, of which the bulk is in 
the small venules and veins [16]. As such, the CO response 
to phenylephrine is very dependent on the starting condition 
of the return function: if the patient is volume replete, with 
good reserves in unstressed volume and minimal initial tone 
in the veins draining the compliant region, phenylephrine 
can recruit unstressed volume into stressed volume by con-
tractions of the smooth muscles in the walls of the vessels of 
the compliant part of the circulation, increasing the venous 
elastic recoil pressure. When this effect is greater than the 
increase in venous resistance, this will result in increased 
venous return and CO [16].
Figure 3 and Table 1 show that 90 s after an initial parallel 
increase in MAP and SVR following phenylephrine admin-
istration, the SVR curve started to decrease steeply, while 
the MAP curve drops more slowly. This dissociation indi-
cates a second phenomenon increasing the blood pressure 
independently of the vascular resistance system. Because 
MAP ~ CO × SVR, an increase in venous return offers an 
additional contribution to the effect of phenylephrine on the 
MAP. The onset of this effect—about 90 s following the 
initial increase in MAP—corresponds to the expected time 
to reach a significant concentration of phenylephrine in the 
venous capacitance vessels. Remarkably, at  T10, the SVR is 
not significantly higher compared to  T−1, while MAP and 
CO are still 24 and 20% higher, respectively (Table 1).
Next, the evolution of CVP—derived from the cen-
tral venous catheter—also demonstrates a centralisation 
of venous blood, resulting in increased right ventricular 
preload, reflecting the postulated effects of phenylephrine 
on capacitance vessels. Even more, despite an increase in 
(left ventricular) CO—which depletes blood from the venous 
side—there is a persistent increase in CVP, implying that a 
higher cardiac preload is the primary driving force of the 
increased CO. This is also reflected in the steep increase 
in SV from 55 to 70 mL between  T−1 and  T5, despite the 
increase in systemic afterload, with no significant change 
in HR (Table 1). As surrogate measures of cardiac preload 
dependency, PPV—determined from the systolic and dias-
tolic blood pressure measurements through the ventilation 
cycle—and SVV also distinctly drop. While PPV is not 
strictly a measure of preload, its decrease indicates a right-
shift of the heart on the Frank–Starling relationship and thus 
a transition from preload dependence to fluid unresponsive-
ness without fluid administration [6]. Since all patients were 
preload dependent, no comparison in hemodynamic effects 
of phenylephrine between preload-dependent and preload-
independent states was possible.
As a separate independent measure, the evolution of the 
 EtCO2—measured by absorption spectrometry—indicates 
an increase in CO following phenylephrine [17, 18]. The 
significant average(SD) increase in  EtCO2 from 38(4) to 
42(5) mmHg during stable ventilatory settings and invari-
ant HR also indicates an increase in CO owing to increased 
cardiac preload.
An important pharmacological consideration is the rather 
long biological half-life of phenylephrine of 2–3 h. While 
clinical experience based on the evolution of the MAP fol-
lowing phenylephrine administration gives the impression 
Fig. 2  The evolution of individual patient variables. The evolution in 
individual patients (thin lines) and average (thick line) values of the 
main preload-dependent variables over the period from 1 min before 
till 12  min after the increase in initial blood pressure following the 
administration of phenylephrine. All measurements are synchronized 
at the moment  (T0) of 10 mmHg increase in MAP following phenyle-
phrine administration
◂
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of a very short half-life, the fast decline of the MAP after 
the initial increase merely reflects the redistribution of the 
phenylephrine, but not its elimination. The long biological 
half-life of phenylephrine permits to reach a clinically signif-
icant plasma concentration in the capacitance vessels. While 
norepinephrine also has a potent α-mimetic effect, it has a 
biological half-life of only 2–6 min [19, 20]. Because of the 
fast enzymatic degradation of norepinephrine [20], the con-
centration in the capacitance vessels remains much lower—
remind that the splanchnic capacitance vessels only receive 
a relatively small fraction of the CO, while harbouring 25% 
of the total blood volume [21]. Given these pharmacoki-
netic differences, the ratio of the effects on CO and MAP 
will arguably be more balanced following phenylephrine 
Fig. 3  The course of the hemodynamic variables after administra-
tion of phenylephrine. The MAP, CVP, HR, PPV, SVV, SV, SVR, 
end-tidal  CO2-concentration  (EtCO2), mean systemic filling pres-
sure (Pmsa), CO and resistance to vascular return (RVR) are shown. 
The graphs are the averages of the individual patient measurements, 
synchronized at the moment  (T0) of 10 mmHg increase in MAP after 
phenylephrine administration
Table 1  Evolution of the 
hemodynamic variables
Mean(SD) evolution of the hemodynamic variables: before administration of phenylephrine  (T−1) and 
5(T5) and 10 min  (T10) after 10% increase in MAP. *P < 0.05 versus  T−1. Median(range) changes in the 
hemodynamic variables between  T−1 and  T5, and between  T−1 and  T10
MAP mean arterial pressure, HR heart rate, EtCO2 end-tidal  CO2 concentration, CVP central venous pres-
sure, CO cardiac output, SV stroke volume, PPV pulse pressure variation, SVV stroke volume variation, 
SVR systemic vascular resistance, Pmsa mean systemic filling pressure, RVR resistance to vascular return, 
Pvr pressure for venous return
T−1 T5 T10 Δ(T5–T−1) Δ(T10–T−1)
MAP (mmHg) 54(8) 88(16)* 67(12)* 34(12; 64) 13(2; 24)
HR (bpm) 72(10) 70(12) 70(11) − 1(− 12; 7) − 2(− 9; 5)
EtCO2 (mmHg) 38(4) 42(5)* 40(5)* 3(0; 7) 2 (0; 6)
CVP (mmHg) 8(5) 11(6)* 9(5) 2(− 1; 9) 0(− 2; 5)
CO (L min−1) 3.92(0.87) 4.94(1.2)* 4.71(1.23)* 0.9(− 0.08; 2.57) 0.55(− 0.31; 2.25)
SV (mL) 55(10) 70(14)* 67(14)* 17(3; 30) 9(− 1; 32)
PPV (%) 20(7) 9(5)* 13(5)* − 11(− 21; − 2) − 6(− 17; − 2)
SVV (%) 19(3) 11(6)* 14(6)* − 8.5(− 15;3) − 6(− 11; 1)
SVR (dyn s cm−5) 1035(305) 1421(499)* 1103(350) 370(80; 930) 80(− 110; 360)
Pmsa (mmHg) 13(4) 18(5)* 15(5)* 4(0; 12) 1(− 1; 7)
RVR (mmHg min L−1) 1.33(0.34) 1.54(0.45)* 1.38(0.38)* 0.09(0; 0.47) 0.02(− 0.06; 0.16)
Pvr (mmHg) 4.97(0.84) 7.02(1.24)* 5.97(1.04)* 1.79(0; 3.81) 0.84(− 0.13; 2.01)
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compared to norepinephrine administration. This should, 
however, be substantiated in further research.
This emphasizes the physiological complexity determin-
ing the ultimate effect of the used vasopressor on the CO: (1) 
the balance of α- and β-adrenoceptor effects, (2) the phar-
macokinetic properties of the vasoactive molecule, and (3) 
the preload dependency of the patient.
Our study has several limitations: firstly, no echocardio-
graphic measurements of diastolic right and left volumes 
were performed to assess the preload effects of phenyle-
phrine. The used ProAQT/Pulsioflex device is yet to be 
formally validated as sufficiently accurate to measure the 
absolute values of the variables of interest. Although cali-
brated devices offer more accurate absolute values, the rela-
tive changes to baseline values can be acceptably described 
by pulse wave contour analysis technology for assessing 
trend changes within a moderate range of acceptable physi-
ological values. Additionally, the accuracy of the calculated 
SV based on wave-contour analysis may have been affected 
by the change in arterial elastance following phenylephrine 
administration [22]. The evolution of the CO, however, is 
only one of several variables indicating an increase in car-
diac filling due to phenylephrine. The particular advantage 
of this device based on fast-reacting algorithms is its high 
temporal resolution, averaging 4 “sliding” intervals of 7.5 s, 
which results in complete recalculation within 30 s [23]. 
Secondly, the patients were rather volume dependent due 
to the combination of vasoplegia by epidural analgesia and 
hypovolemia by bowel preparation, which may explain the 
distinct effects observed in this study, compared to other 
reports. Thirdly, atropine was administered at the start of 
anesthesia to attenuate the negative effects on the MAP and 
CO after induction with TIVA [24]. This doesn’t influence 
the effects of phenylephrine on the venous return, but it 
probably blunts the reflex bradycardia induced by phenyle-
phrine. While this is beneficial to more clearly demonstrate 
the effects on the venous return and global hemodynamics, 
it may narrow the external validity of its beneficial effects on 
the CO. Fourthly, Pmsa and Pvr values were derived math-
ematically and therefore, coupled with CO. Ideally, these 
values should have been assessed independently of CO. In 
our study, this was not done because the inspiratory hold 
manoeuvres to measure Pmsa would have unavoidably dis-
turbed the accuracy of the primary research variables. The 
algorithm to calculate Pmsa and Pvr was validated previ-
ously [25]. Finally, no radiographic confirmation of the tip 
of the central venous catheter was performed at the time of 
CVP measurement. While this would arguably have minor 
influence on the calculated changes to baseline values of the 
studied variables, it may have affected the accuracy of the 
CVP measurements.
With respect to the described limitations, the current 
results must be interpreted within the constraints of potential 
shortcomings. Neither preload, contractility nor afterload 
were directly measured by the pulse contour technology. 
While the observed results suggest an improvement of 
venous return by virtue of phenylephrine administration, 
further research relying on direct measurements, like ech-
ography or thermodilution will be needed to fully describe 
the changes in cardiac preload, contractility and afterload in 
these clinical conditions.
In this study, the evolution of the hemodynamic vari-
ables was investigated after injection of a single dose of 
phenylephrine. This strategy was selected in order to most 
reliably depict the chronology of the hemodynamic changes. 
Additional research investigating the hemodynamic effects 
of phenylephrine in different baseline preload states may 
further elucidate the preload-dependency of these compound 
effects. The effects during continuous infusion on the inves-
tigated variables will have to be precisely determined, as 
well as comparison with the effects of alternative vasopres-
sors. Ideally, an independent measure of CO, such as ultra-
sound or thermodilution should have been used to confirm 
the observed evolution of waveform-derived variables.
4.1  Clinical implications
The prospect to optimize cardiac preload with considerably 
less fluid administration offers significant clinical advantages 
but adds complexity due to differences in pharmacokinetics 
and patient characteristics. Excessive administration of vaso-
pressors may jeopardize organ perfusion, which underlines 
the importance of advanced hemodynamic monitoring to 
assess the evolution of the hemodynamic variables for the 
guidance of the hemodynamic management. In summary, 
in preload-dependent patients with low SVR, vasopressors 
could be preferable, while in preload-dependent patients 
with high SVR, volume administration would be a better 
choice. Meticulous trend assessment of different indices of 
CO, volume responsiveness and SVR is imperative to indi-
vidualize the optimal drug dose to maximise centralisation 
of blood while avoiding harmful effects on cardiac afterload 
and organ perfusion.
5  Conclusions
This study indicates that in preload-dependent patients, 
phenylephrine increases the CO by virtue of an increase in 
cardiac filling. This is manifested by several distinct hemo-
dynamic indices of CO and venous return, namely the dis-
sociation of MAP and SVR, CVP, PPV, CO, and  EtCO2, in 
addition to the derived variables SV, SVV, Pmsa, Pvr and 
RVR.
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